fbpx Skip to main content

TUESDAY, Sept. 15, 2020 (HealthDay News) — For patients with psoriasis, lipid-rich necrotic core (LRNC) is associated with psoriasis severity and cardiovascular risk factors and is reduced for those patients receiving biologic therapy, according to a study published online Sept. 15 in Circulation: Cardiovascular Imaging.

Harry Choi, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues characterized LRNC in 209 biologically naive psoriasis patients who underwent coronary artery computed tomography angiography at baseline and one year. Histopathologically validated software was used to assess changes in LRNC before and after biologic therapy over one year.

The researchers found that LRNC was associated with Framingham risk score and psoriasis severity in all participants at baseline. At one year, a reduction in LRNC was seen in participants receiving biologic therapy (3.12 versus 2.97 mm²), while no significant change was seen for those who did not receive biologic therapy (3.12 versus 3.34 mm²). Compared with the change in the non-biologic-treated group, the change in LRNC in those receiving biologic therapy was significant (−0.22 versus 0.14 mm²); after adjustment for cardiovascular risk factors and psoriasis severity, the change remained significant.

“We specifically demonstrated the beneficial effects of biologic therapy on LRNC, and these findings provide important insight into the potential stabilization and reversibility of LRNC in the coronary artery,” the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

You May Also Like::  Willingness to Get COVID-19 Vaccine Up in Health Care Workers

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More